METHODS OF TREATING BACTERIAL INFECTIONS
Methods of treating bacterial infection in immunocompromised subjects and subjects with one or more underlying malignancies include administering a combination of meropenem and vaborbactam to the subject. Suitable subjects to be treated can include a subject with a history of ongoing leukemia or lymphoma, a subject that has had an organ transplant, stem cell transplant, bone marrow transplant, or splenectomy, a subject receiving immunosuppressive medications, a subject receiving bone marrow ablative chemotherapy, a subject with neutropenia and subject suffering from or having suffered from a malignancy.
1 . A method of treating one or more bacterial infection in a subject, wherein the subject is suffering from or has suffered from a malignancy, wherein the malignancy is selected from the group consisting of a hematological malignancy and a solid tumor, comprising administering to the subject in need thereof a combination of meropenem and vaborbactam.
2 . The method of claim 1 , wherein the bacterial infection is selected from the group consisting of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter cloacae species complex, Enterococcus faecium, Serratia marcescens, Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, Chlamydia trachomatis, Mycoplasma pneumoniae, Legionella pneumophila, Acinetobacter baumannii, Bartonella bacilliformis, Brucella species, Calymmatobacterium granulomatis, Campylobacter fetus, Francisella tularensis, Haemophilus ducreyi, Vibrio cholerae , and Yersinia pestis.
3 . The method of claim 1 , wherein the malignancy is a hematological malignancy, and wherein the hematological malignancy is selected from the group consisting of acute lymphocytic leukemia, acute myeloid leukemia, AIDS-related lymphoma, primary CNS lymphoma, Burkitt lymphoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin lymphoma, leukemia, multiple myeloma, myoproliferative neoplasms, and Sezary syndrome.
4 . The method of claim 1 , wherein the malignancy is a solid tumor, and wherein the solid tumor is a sarcoma or carcinoma.
5 . The method of claim 1 , wherein the subject has an absolute neutrophil count below about 1000 cells/mm 3 .
6 . The method of claim 1 , wherein the administration is oral, intravenous, intraperitoneal, intragastric, or intravascular administration.
7 . The method of claim 1 , wherein the dose of the meropenem administered is between 1 mg and 5000 mg and the dose of the vaborbactam administered is between 1 mg and 5000 mg.
8 . The method of claim 7 , wherein the dose of meropenem is 10 mg to 3000 mg and the dose of vaborbactam is 10 mg to 3000 mg.
9 . The method of claim 7 , wherein the dose of meropenem is 100 mg to 2000 mg and the dose of vaborbactam is 100 mg to 2000 mg.
10 . The method of claim 1 , wherein the meropenem and vaborbactam are administered in a weight ratio from 2:1 to 1:2.
11 . The method of claim 1 , wherein the meropenem and the vaborbactam are administered from one to four times daily, and wherein the meropenem and vaborbactam are administered from about 1 day to at least about 4 weeks.
12 . The method of claim 1 , wherein the meropenem and vaborbactam are administered simultaneously.